Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30

$44.46−1.23 (-2.69%)

Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –

Rigel Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Rigel Pharmaceuticals's EV/EBITDA was 8.7× on Nov 11, 2026, against 6.5× a year earlier. Over the last 3 years it ranged from 2.7× to 37.1×, with a median of 9.5×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	8.7×	+3.3
2025	Dec 31, 2025	5.3×	−15.1
2024	Dec 31, 2024	20.5×	+7.8
2012	Feb 29, 2012	12.7×	−2.1
2011	Dec 30, 2011	14.8×	–

Where these numbers come from

Parsed from the XBRL in Rigel Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 27, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing